Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant women ≥18 years of age~* Patient is diagnosed with ESRD and must be on hemodialysis 3 times per week for at least 3 months prior to Screening Phase~* Patient is currently being treated with pharmaceutical vitamin D for the treatment of secondary hyperparathyroidism~* Serum iPTH value ≤500 pg/mL at first screening visit~* Total serum calcium (corrected for albumin) ≤10.5 mg/dL at first screening visit~* Serum phosphorus ≤7.0 mg/dL at first screening visit~Exclusion Criteria:~* Currently taking any of the following: drugs affecting vitamin D metabolism, digitalis, glucocorticoids, cyclosporine or other immunosuppressants, aluminum-based phosphate binders~* A daily intake \>4000 IU vitamin D (D3 + D2)~* Any investigational drug use within 10 half-lives of the drug (or within the previous 30 days if the half-life of the drug is unknown)~* History of any of the following: ventricular dysrhythmias, severe congestive heart failure, angina pectoris, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, multiple myeloma, calciphylaxis, active malignancy, end-stage liver disease, active infections, clinically significant renal/urinary tract stones, sarcoidosis, tuberculosis, parathyroidectomy~* Major surgery within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DP001 (Type: EXPERIMENTAL): DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).